Pre-TCR-targeted immunotherapy for T cell acute lymphoblastic leukemia Summary Pre-TCR-targeted immunotherapy aims to eliminate leukemic T cells in T cell acute lymphoblastic leukemia (T-ALL) by targeting the T cell receptor (TCR) before it fully assembles. Read More
Nature Immunology, Published online: 29 August 2025; doi:10.1038/s41590-025-02274-9 T cells in space and time Summary A Nature Immunology article published on August 29, 2025, explores the dynamic behavior of T cells within the context of Read More
Nature Immunology, Published online: 29 August 2025; doi:10.1038/s41590-025-02272-x LPS structure shapes Treg cells Summary A 2025 Nature Immunology study reveals that the structure of lipopolysaccharide (LPS), a major component of gram-negative bacteria, significantly influences Read More
Nature Immunology, Published online: 29 August 2025; doi:10.1038/s41590-025-02273-w Humanized mice for MS studies Summary A new study in Nature Immunology (August 29, 2025) highlights the development of humanized mice for studying Multiple Sclerosis (MS). The Read More
Nature Immunology, Published online: 29 August 2025; doi:10.1038/s41590-025-02271-y Antiphage SIR2 in humans Summary A Nature Immunology paper published online on August 29, 2025, reveals a novel antiphage defense mechanism mediated by SIR2 in humans. The Read More
Nature Immunology, Published online: 29 August 2025; doi:10.1038/s41590-025-02256-x IRF3 initiates type I IFN transcription, and this is required for host defense. Here, Chen and colleagues show that RAD18 terminates the transcriptional activity of Read More
Nature Immunology, Published online: 29 August 2025; doi:10.1038/s41590-025-02255-y Alatrakchi and colleagues profile immune cells from liver and blood obtained from patients with MASLD/MASH using single-cell sequencing. They note increased immunoregulatory programs that Read More
Nature Immunology, Published online: 27 August 2025; doi:10.1038/s41590-025-02252-1 TCR-T cells are T cells engineered to express a specific T cell receptor. Here the authors present a TCR-T cell that targets CTNNB1-S37F, Read More
Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial Summary A correction was issued regarding the phase 2 SWOG S1512 trial, which investigated anti-PD-1 therapy (pembrolizumab) for unresectable desmoplastic melanoma. The correction Read More
Nature Immunology, Published online: 22 August 2025; doi:10.1038/s41590-025-02247-y Using in vivo CRISPR–Cas9 screens of CD8+ T cells in a melanoma model, we identified STUB1 as an inhibitor of T cell-mediated antitumor immunity. Read More
1 Million+ Views and Counting..!
It has been 7 years since it was launched in late July 2018, and it is moving forward. Appreciate all the respected visitors! Please share this site with your friends to push science forward and improve human health.
